Short Interest in Eyenovia, Inc. (NASDAQ:EYEN) Increases By 346.2%

Eyenovia, Inc. (NASDAQ:EYEN) was the recipient of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 249,400 shares, an increase of 346.2% from the January 31st total of 55,900 shares. Based on an average daily volume of 366,000 shares, the days-to-cover ratio is presently 0.7 days. Currently, 12.1% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. William Blair reaffirmed a “market perform” rating on shares of Eyenovia in a research report on Friday, November 15th. HC Wainwright reissued a “neutral” rating and set a $2.00 price objective on shares of Eyenovia in a report on Thursday, February 6th. Brookline Capital Management reissued a “hold” rating on shares of Eyenovia in a report on Friday, November 15th. Finally, LADENBURG THALM/SH SH reissued a “neutral” rating on shares of Eyenovia in a report on Monday, November 18th.

Institutional Trading of Eyenovia

A hedge fund recently raised its stake in Eyenovia stock. Geode Capital Management LLC grew its holdings in Eyenovia, Inc. (NASDAQ:EYEN) by 36.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 557,994 shares of the company’s stock after buying an additional 149,471 shares during the quarter. Geode Capital Management LLC owned approximately 0.87% of Eyenovia worth $288,000 at the end of the most recent reporting period. 25.84% of the stock is currently owned by institutional investors.

Eyenovia Stock Down 1.7 %

Shares of NASDAQ EYEN opened at $1.69 on Friday. The stock has a market cap of $2.35 million, a PE ratio of -0.03 and a beta of 1.24. The business has a fifty day moving average of $4.91 and a two-hundred day moving average of $22.82. Eyenovia has a 52-week low of $1.43 and a 52-week high of $205.60. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.55 and a current ratio of 0.74.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.